Skip to main content

Advertisement

Volume 3 Supplement 1

ESICM LIVES 2015

Inhaled ceftazidime and amikacin versus inhaled colistin in the treatment of gram negative ventilator associated pneumonia

Article metrics

  • 451 Accesses

Introduction

Aerosol antibiotics administration offers the theoretical advantages of achieving high drug concentrations at the infection site and low systemic absorption.

Objectives

Comparing the microbiological outcome of inhaled ceftazidime amikacin versus inhaled colistin as adjunctives to conventional iv antibiotics in treating gram negative VAP.

Methods

This prospective randomized controlled study was carried out on 60 mechanically ventilated patients with gram negative VAP.

Inclusion criteria: Adult mechanically ventilated patients diagnosed to have Gram negative VAP confirmed:· Radiologically (new chest x- ray infiltrate).

· Microbiologically (positive culture from aspirate of endo- tracheal tube (ETT).

· Clinically (fever, leukocytosis and increased bronchial secretion). CPIS scoring >6.

E xclusion criteria:· Severe renal impairment,

The patients included in the study were equally randomized to enter one of 3 groups; group A, group B or group C.

· Group (A) 20 patients: nebulized ceftazidime (15 mg.kg. 3 h) plus nebulized amikacin (25 mg·kg·d) in addition to conventional IV antibiotics.

· Group (B) 20 patients: nebulized Colistin (1million IU every 8h) in addition to

conventional IV antibiotics.

· Group (C) 20 patients: conventional IV antibiotics.

In all groups A,B and C, treatment was continued for five days followed by ETT aspirate.

Interpretation of culture results:

Clearance: no growth. Resistance: persistent pathogen. Super infection: eradication of previous pathogen with developing of another pathogen. Resistance and super infection: persistent responsible pathogen with developing of another pathogen.

Results

The clearance of organism was (75% vs. 80% vs. 50%), resistance was (5% vs. 5% vs. 20%), superinfection was (0% vs. 10% vs. 15%), while combined resistance and super infection was (20% vs. 5% vs. 15%) in group A vs. B vs. C respectively.

Comparing group B vs. C: a significantly greater clearance (80% vs. 50%, p 0.047) while no significant difference regarding resistance (5% vs. 20%, p 0.151), superinfection (2% vs. 15%, p 0.633), combined resistance and super infection (5% vs. 15%, p 0.292) in group B vs. C respectively.

Comparing group A vs. C: no significant difference in clearance (75% vs.50%, p 0.102), resistance (5% vs. 20%, p 0.151), superinfection (0% vs. 15%, p 0.072), combined resistance and super infection (20% vs. 15%, p 0.667) in group A vs. C respectively.

Comparing group A vs. B: no significant difference in clearance (75% vs.80%, p 0.705), resistance (5% vs. 5%, p 1.0), superinfection (0% vs. 10%, p 0.147), combined resistance and super infection (20% vs. 5%, p 0.151) in group A vs. B respectively.

Conclusions

The addition of Inhaled Colistin showed a significantly better organism clearance after 5 days compared to inhaled Ceftazidime and Amikacin and compared to iv antibiotics without additional inhaled antibiotics, in treating gram negative VAP.

Grant Acknowledgment

Cairo University

Author information

Correspondence to YS Nassar.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nassar, Y., Ibrahim, M., Salman, A. et al. Inhaled ceftazidime and amikacin versus inhaled colistin in the treatment of gram negative ventilator associated pneumonia. ICMx 3, A380 (2015) doi:10.1186/2197-425X-3-S1-A380

Download citation

Keywords

  • Ceftazidime
  • Amikacin
  • Colistin
  • Prospective Randomized Control Study
  • Grant Acknowledgment